Tuesday, August 25, 2026

China’s Strategic Shift: What Xi Jinping’s Visit to North Korea Means for Nuclear Power in 2026

Xi Jinping's visit to North Korea marks a shift in China's stance, emphasizing military cooperation over denuclearization concerns.

Coupang Data Breach: How an ISDS Claim Could Spark an International Dispute

Coupang faces international arbitration over a data breach, with U.S. shareholders claiming unfair treatment by South Korea's government.

South Korea Reaffirms U.S. Understanding as Jangbogo-N Nuclear Submarine Plan Moves Forward

The government addressed concerns over the 'Jangbogo N project', stating there was prior communication with the U.S. regarding nuclear submarines.

Tag: Truxima

How Celltrion’s Truxima Dominates the U.S. Rituximab Market: A 4-Month Winning Streak

Celltrion's Truxima leads the U.S. rituximab market for four months, gaining FDA interchangeability status, boosting growth prospects.

Celltrion’s Truxima becomes first rituximab biosimilar in U.S. to receive interchangeability designation

Celltrion's Truxima gains FDA interchangeability status, enhancing its market position and credibility in blood cancer treatment.

Truxima: How the First Korean Biosimilar Achieved 35.8% Market Share in the U.S.!

Celltrion’s Truxima becomes South Korea's first biosimilar to lead U.S. prescription market, boosted by tariff exemptions and strong growth.

Top News

- Our Sponsors Ad -

Follow us